Glucocorticoids and Lipocortin

  • S. H. Peers
  • R. J. Flower
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 87 / 2)


The steroids are the most useful anti-inflammatory drugs that we possess, effective against virtually any type of inflammation. The naturally occurring hormone hydrocortisone is still used in clinical medicine, but in many cases it has been superseded by synthetic analogues which have vastly increased duration of action and potency, making them particularly valuable to the dermatologist. As a group, the steroidal anti-inflammatories are amongst the most widely prescribed drugs in the world.


Systemic Lupus Erythematosus Glucocorticoid Receptor Arachidonic Acid Release Prostaglandin Biosynthesis Eicosanoid Synthesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aarsman AJ, Mynbeek G, Van Den Bosch H, Rothhut B, Prieur B, Cornera C, Jordon L, Russo-Marie F (1987) Lipocortin inhibtion of extracellular and intracellular phospho-lipase A2 is substrate concentration-dependent. FEBS Lett 219:76–180CrossRefGoogle Scholar
  2. Blackwell GJ (1983) Specificity and inhibition of glucocorticoid-induced macrocortin secretion from rat peritoneal macrophages. Br J Pharmacol 79:587–594PubMedGoogle Scholar
  3. Blackwell GJ, Carnuccio R, di Rosa M, Flower RJ, Parente L, Persico P (1980) Macrocortin: a polypeptide causing the antiphospholipase effect of glucocorticoids. Nature 287:147–149PubMedCrossRefGoogle Scholar
  4. Blackwell GJ, Carnuccio R, di Rosa M, Flower RJ, Langham CSJ, Parente L, Persico P et al. (1982) Glucocorticoids induce the formation and release of anti-inflammatory and anti-phospholipase proteins into the peritoneal cavity of the rat. Br J Pharmacol 76:185–194PubMedGoogle Scholar
  5. Caliagnano A, Carnuccio R, di Rosa M, Ialenti A, Moncada S (1985) The anti-inflammatory effect of glucocorticoid-induced phospholipase inhibitory proteins. Agents Actions 16:60–62CrossRefGoogle Scholar
  6. Carnuccio R, di Rosa M, Flower RJ, Pinto A (1980) Hydrocortisone-induced inhibitor of prostaglandin biosynthesis in rat leukocytes. Br J Pharmacol 68:14–16PubMedGoogle Scholar
  7. Carnuccio R, di Rosa M, Flower RJ, Pinto A (1981) The inhibition by hydrocortisone of prostaglandin biosynthesis in rat peritoneal leukocytes is correlated with intracellular macrocortin levels. Br J Pharmacol 74:322–324PubMedGoogle Scholar
  8. Carnuccio R, di Rosa M, Guerrasio B, Iuvone T, Sautebin L (1987) Vasocortin, a novel glucocorticoid-induced anti-inflammatory protein. Br J Pharmacol 90:443–445PubMedGoogle Scholar
  9. Cirino G, Flower RJ (1987 a) Human recombinant lipocortin I inhibits prostacyclin production by human umbilical artery. Prostaglandins 34:59–62PubMedCrossRefGoogle Scholar
  10. Cirino G, Flower RJ (1987 b) The inhibitory effect of lipocortin on eicosanoid synthesis is dependent on divalent cation. Br J Pharmacol 92:521PGoogle Scholar
  11. Cirino G, Flower RJ, Browning J, Sinclair LK, Pepinsky RB (1987) Recombinant human lipocortin I inhibits thromboxane release from guinea-pig isolated perfused lung. Nature 328:270–272PubMedCrossRefGoogle Scholar
  12. Cirino G, Peers SH, Flower RJ, Browning J, Pepinsky RB (1989) Human recombinant lipocortin I has acute local anti-inflammatory properties in the rat paw oedema test. Proc Natl Acad Sci USA (in press)Google Scholar
  13. Cloix JF, Colard O, Rothhut B, Russo-Marie F (1983) Characterisation and partial purification of “renocortins”, two polypeptides formed in renal cells causing the anti-phos-pholipase-like action of glucocorticoids. Br J Pharmacol 79:313–321PubMedGoogle Scholar
  14. Danon A, Assouline G (1978) Inhibition of prostaglandin biosynthesis by corticosteroids requires RNA and protein synthesis. Nature 273:552–554PubMedCrossRefGoogle Scholar
  15. Davidson FF, Dennis EA, Powell M, Glenney JR (1987) Inhibition of phospholipase A2 by “lipocortins” and calpactins. An effect of binding to substrate phospholipids. J Biol Chem 262:1698–1705PubMedGoogle Scholar
  16. Dawes PT, Ilchyshyn A, Goulding NJ, Ilderton E, Shadforth MF, Yardley H, Hall ND (1987) Elevated epidermal PLA2 activity in RA: evidence against a circulating lipocortin antibody. Br J Rheumatol [Suppl 1]26:62CrossRefGoogle Scholar
  17. Di Rosa M, Persico P (1979) Mechanism of inhibtion of prostaglandin biosynthesis by hydrocortisone in rat leukocytes. Br J Pharmacol 66:161–163PubMedGoogle Scholar
  18. Di Rosa M, Flower RJ, Hirata F, Parente L, Russo-Marie F (1984) Nomenclature announcement. Anti-phospholipase proteins. Prostaglandins 28:441–442PubMedCrossRefGoogle Scholar
  19. Flower RJ (1984) Macrocortin and the antiphospholipase proteins. In: Weissman G (ed) Advances in inflammation research, vol 8. Raven, New York, p 1Google Scholar
  20. Flower RJ (1985) Background and discovery of lipocortins. Agents Actions 17:255–262CrossRefGoogle Scholar
  21. Flower RJ, Blackwell GJ (1979) Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 278:456–459PubMedCrossRefGoogle Scholar
  22. Flower RJ, Wood JN, Parente L (1984) Macrocortin and the mechanism of action of the glucocorticoids. In: Otterness I, Capetola R, Wong S (eds) Advances inflammation research, vol 7. Raven, New York, p 61Google Scholar
  23. Flower RJ, Moon-Parvin D, Peers SH, Pepinsky RB, Taylor RD (1986) A novel assay for assessing the binding of phospholipase A2 to substrate. Br J Pharmacol 89:743PGoogle Scholar
  24. Forster S, Ilderton E, Summerley R, Yardley HJ (1983) The level of phospholipase A2 activity is raised in the univolved epidermis of psoriasis. Br J Dermatol 108:103–105PubMedCrossRefGoogle Scholar
  25. Forster S, Ilderton E, Norris JFB, Summerly R, Yardley HJ (1984) Characterization and activity of phospholipase A2 in normal human epidermis and lesion-free epidermis of patients with psoriasis or eczema. Br J Dermatol 112:135–147CrossRefGoogle Scholar
  26. Ghiara P, Meli R, Parente L, Perscio P (1984) Distinct inhibition of membrane-bound and lysosomal phospholipase A2 by glucocorticoid-induced proteins. Biochem Pharmacol 33:1445–1450PubMedCrossRefGoogle Scholar
  27. Gryglewski RJ, Panczenko B, Korbut R, Grodzinska L, Ocetkiewicz A (1975) Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessies of rabbit and from perfused lungs of sensitized guinea-pigs. Prostaglandins 10:343–355PubMedGoogle Scholar
  28. Gupta C, Goldman A (1982) H-2 histocompatibility region: influence on the murine glucocorticoid receptor and its response. Science 216:994–996PubMedCrossRefGoogle Scholar
  29. Gupta C, Katsumo M, Goldman AS, Piddington R, Herold R (1984) Glucocorticoid-in-duced phospholipase A2 inhibitory proteins mediate glucocorticoid teratogenicity in vitro. Proc Natl Acad Sei USA 81:1140–1143CrossRefGoogle Scholar
  30. Hattori T, Hoffman T, Hirata F (1983) Differentitation of a histiocytic lymphoma cell line by lipomodulin, a phospholipase inhibitory protein. Biochem Biophys Res Commun 111:551–559PubMedCrossRefGoogle Scholar
  31. Herbaczynska-Cedro K, Staszewska-Barczak J (1974) Adrenocortical hormones and the release of prostaglandin-like substances (PLS) (Abstr). 2nd Congress of the Hungarian Pharmacological Society, BudapestGoogle Scholar
  32. Hirata F (1981) The regulation of lipomodulin, a phospholipase inhibitory protein, in rabbit neutrophils by phosphorylation. J Biol Chem 256:7730–7733PubMedGoogle Scholar
  33. Hirata F, Iwata M (1983) Role of lipomodulin, a phospholipase inhibitory protein, in im-munoregulation by thymocytes. J Immunol 130:1930–1936PubMedGoogle Scholar
  34. Hirata F, Schiffmann E, Venkatasubramanian K, Salomon D, Axelrod J (1980) A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA 77:2533–2536PubMedCrossRefGoogle Scholar
  35. Hirata F, Delcarmine R, Nelsom CA, Axelrod J, Schiffmann E, Warabi A, Deblas AL et al. (1981) Presence of autoantibody for phospholipase inhibitory protein(s) by radioim-muno-assay for lipomodulin. Biochem Biophys Res Commun 78:3190–3194Google Scholar
  36. Hirata F, Notsu Y, Iwata M, Parente L, di Rosa M, Flower RJ (1982) Identification of several species of phospholipase inhibitory protein(s) by radioimmuno-assay for lipomodulin. Biochem Biophys Res Commun 109:223–230PubMedCrossRefGoogle Scholar
  37. Hirata F, Matsuda K, Notsu Y, Hattori T, Delcarmine R (1984) Phosphorylation at a tyrosine residue of lipomodulin in mitogen-stimulated murine thymocytes. Proc Natl Acad Sci USA 81:4717–4721PubMedCrossRefGoogle Scholar
  38. Hirata F, Notsu Y, Yamada R, Ishihara Y, Wano Y, Kunos I, Kunos G (1985) Isolation and characterisation of lipocortin (lipomodulin) Agents Actions 17:263–266CrossRefGoogle Scholar
  39. Hong SC, Levine L (1976) Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory steroids. Proc Natl Acad Sci USA 73:1720–1734CrossRefGoogle Scholar
  40. Huang K-S, Wallner BP, Mattaliano RJ, Tizard R, Burne C, Frey A, Hession C et al. (1986) Two human 35 kd inhibitors of phospholipase A2 are related to substrates to pp60v-src and of the epidermal growth factor receptor/kinase. Cell 46:191–199PubMedCrossRefGoogle Scholar
  41. Huang K-S, McGray P, Mattaliano RJ, Burne C, Chow EP, Sinclair LK, Pepinsky RB (1987) Purification and characterisation of proteolytic fragments of lipocortin I that inhibit phospholipase A2. J Biol Chem 262:7639–7645PubMedGoogle Scholar
  42. Ilchyshyn A, Ilderton E, Kingsbury JA, Yardley HJ (1984) Evidence that the raised level of phospholipase A2 in the uninvolved epidermis of psoriasis is caused by hyperphos-phorylation of an inhibitor. Br J Dermatol 111:721–722Google Scholar
  43. Ilchyshyn A, Ilderton E, Yardley HJ (1985) Further evidence that the raised level of phospholipase A2 in lesion-free epidermis of psoriasis is caused by hyperpolarisation of an inhibitor. Br J Dermatol 112:135–147CrossRefGoogle Scholar
  44. Ilchyshyn A, Ilderton E, Pepinsky B, Yardley HJ (1986) Inhibition of phospholipase A2 activity in extracts of psoriatic epidermis by lipocortin. 4th International Symposium on Psoriasis, Stanford, USAGoogle Scholar
  45. Koltai M, Lepran I, Nemecz GY, Szekeres L (1983) The possible mechanism of protection induced by dexamethasone against sudden death due to coronary ligation in concious rats. Br J Pharmacol 79:327–329PubMedGoogle Scholar
  46. Koltai M, Tosaki A, Adam G, Joo F, Nemecz G, Stezekeres L (1984) Prevention by mac-rocortin of global cerebral ischaemia in Sprague-Dawley rats. Eur J Pharmacol 105:347–350PubMedCrossRefGoogle Scholar
  47. Koltai M, Kovacs Z, Nemecz G, Mecs I, Szekeres L (1987) Glucocorticoid-induced low molecular mass anti-inflammatory factors which do not inhibit phospholipase A2. Eur J Pharmacol 134:109–112PubMedCrossRefGoogle Scholar
  48. Kretsinger RH, Creutz CE (1986) Consensus in exocytosis. Nature 320:573PubMedCrossRefGoogle Scholar
  49. Nijkamp FP, Flower RJ, Moncada S, Vane JR (1976) Partial purification of rabbit aorta contracting substance-releasing factor and inhibition of its activity by anti-inflammatory steroids. Nature 263:479–482PubMedCrossRefGoogle Scholar
  50. Nixon JS, Wilkinson SE, Davis P, Bloxham DP (1985) The inhibitory profiles of hog pancreatic and human rheumatoid synovial cell phospholipase A2. Agents Actions 17:299–301CrossRefGoogle Scholar
  51. Norris JFB, Ilderton E, Yardley HJ, Summerly R, Forster S (1984) Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol [Suppl 27]121:195–203CrossRefGoogle Scholar
  52. Okamoto M, Ono T, Tojo H, Yamano T (1985 a) Immunochemical relatedness between secretory phospholipase A2 and intracellular phospholipase A2. Biochem Biophys Res Commun 128:788–794PubMedCrossRefGoogle Scholar
  53. Okamoto M, Tojo H, Ono T, Yamano T (1985 b) Comparative study of intracellular and pancreatic phospholipase A2. Adv Prostaglandin Thromboxane Leukotriene Res 15:135Google Scholar
  54. Parente L, Flower RJ (1985) Hydrocortisone and “macrocortin” inhibit the zymosan-in-duced release of lyso-PAF from rat peritoneal leukocytes. Life Sci 36:1225–1231PubMedCrossRefGoogle Scholar
  55. Parente L, di Rosa M, Flower RJ, Ghiara P, Meli R, Persico P, Salmon JA, Wood JN (1984) Relationship between the anti-phospholipase and anti-inflammatory effects of glucocorticoid-induced proteins. Eur J Pharmacol 99:233–239PubMedCrossRefGoogle Scholar
  56. Peers SH, Taylor RD, Flower RJ (1987) A novel binding assay for phospholipase A2. Biochem Pharmacol 36:4287–4291PubMedCrossRefGoogle Scholar
  57. Pepinsky RB, Sinclair LK (1986) Epidermal growth factor-dependent phosphorylation of lipocortin. Nature 321:81–84PubMedCrossRefGoogle Scholar
  58. Pepinsky RB, Sinclair LK, Browning JL, Mattaliano RJ, Tizard R, Burnes C, Frey A et al. (1986) Two human 35 kd inhibitors of phospholipase A2 are related to substrates of pp60v-src and of the epidermal growth factor receptor kinase. Cell 46:191–199CrossRefGoogle Scholar
  59. Podgorski MR, Goulding NJ, Hall ND, Flower RJ, Maddison PJ, Pepinsky RB (1987) Autoantibodies to recombinant lipocortin in RA and SLE. Br J Rheumatol [Suppl l]26:54–55Google Scholar
  60. Rothhut B, Russo-Marie F, Wood J, di Rosa M, Flower RJ (1983) Further characterisation of the glucocorticoid-induced anti-phospholipase protein “renocortin”. Biochem Biophys Res Commun 117:878–884PubMedCrossRefGoogle Scholar
  61. Rothhut B, Cumera C, Prieur B, Errasfa M, Minassion G, Russo-Marie F (1987) Purification and characterisation of a 32 kDa phospholipase A2 inhibitory protein (lipocortin) from human peripheral blood mono-nuclear cells. FEBS Lett 219:169–175PubMedCrossRefGoogle Scholar
  62. Russo-Marie F, Duval D (1982) Dexamethasone-induced inhibition of prostaglandin production does not result from a direct action on phospholipase activities but is mediated through a steroid-inducible factor. Biochim Biophys Acta 712:177–185PubMedGoogle Scholar
  63. Russo-Marie F, Paing M, Duval D (1979) Involvement of glucocorticoid receptors in steroid-induced inhibition of prostaglandin synthesis. J Biol Chem 254:8498–8504PubMedGoogle Scholar
  64. Saris CJM, Tack BF, Kristensen T, Glenney JR, Hunter T (1986) The cDNA sequence for the protein-tyrosine kinase substrate p36 (calpactin 1 heavy chain) reveals a multi-domain protein with internal repeats. Cell 46:201–212PubMedCrossRefGoogle Scholar
  65. Schlaepfer DD, Haigier HT (1987) Characterisation of Ca2+-dependent phospholipid binding and phosphorylation of lipocortin I. J Biol Chem 262:6931–6937PubMedGoogle Scholar
  66. Touqui L, Rothhut B, Shaw AM, Fradin A, Vargaftig BB, Russo-Marie F (1986) Platelet activation — a role for a 40k anti-phospholipase A2 protein indistinguishable from lipocortin. Nature 321:177–180PubMedCrossRefGoogle Scholar
  67. Tsurufuji S, Sugio K, Takemasa F (1979) The role of glucocorticoid receptor and gene expression in the anti-inflammatory action of dexamethasone. Nature 280:408–410PubMedCrossRefGoogle Scholar
  68. Van de Velde VJS, Bult H, Herman AG (1985) Dexamethasone and prostacyclin biosynthesis by serosal membranes of the rabbit peritoneal cavity. Agents Actions 17:308–309CrossRefGoogle Scholar
  69. Volwerk JJ, de Haas GH (1982) Pancreatic phospholipase A2: a model for membrane-bound enzymes? In: Jost PC, Griffiths OH (eds) Lipid-protein interactions, vol 1. Wiley, New York, pp 69–149Google Scholar
  70. Wallner BP, et al. (1986) Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 320:77–81PubMedCrossRefGoogle Scholar
  71. Yedgar S, Reisfeld N, Dagan A (1986) Synthesis of cell-impermeable inhibitor of phospholipase A2. FEBS Lett 200:165–168PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • S. H. Peers
  • R. J. Flower

There are no affiliations available

Personalised recommendations